Growth soft vs guidance; Aequitas entry strategic but margins thin

₹82.2 Cr revenue, 8.8% YoY (Q1 FY26 ≈ ₹75.5 Cr implied)

₹13.2 Cr PAT, 22.2% YoY growth delivered

₹19 Cr EBITDA stated at 23% margin; implies prior quarter ~₹15.7 Cr

Secondary sales 18.9% but primary/reported growth only 9%—10 percentage point gap

Q1 at 9% is below implied run rate; acceleration needed to hit 12-15%

Entered hospital segment via 85% stake acquisition (₹20.8 Cr) in ₹53 Cr FY26 revenue company. Strategic new pillar but margins thinner (implied ~15-18%) vs core 65%+; integration complexity increases risk.

Q1 FY27 at 9% revenue growth vs prior guidance of 12-15% for full FY27. While management reiterated 1.5x IPM aim, near-term delivery soft; implied acceleration needed H2 to meet year target.

Operating margin reached 21% (up 240 bps YoY); PAT margin 15.5% (up 176 bps). Brand-mix shift to semi-chronic and premiumization starting to flow through; productivity initiatives yielding results.

Maintained dual M&A + shareholder return approach: completed ₹40 Cr buyback (now holds ₹170 Cr cash); Aequitas spend ₹20.8 Cr. Prior Yash Pharma acquisition (₹90 Cr) integrating; discipline visible but allocation now split across organic, inorganic, and buyback.

Primary vs secondary sales distinction; inventory buffers always present. Pharmarack samples geographies where JPL underrepresented; statistical corrections can cause temporary variance. Both should move in tandem long-term.

Targeting 1.5x IPM on both metrics; inventory build buffers expected. Confident guidance objective remains intact.

Mix improvement from cross-sell of high-margin Jagsonpal brands into hospitals; new innovative products targeted at premium tier. Promoters stay as 15% minority; incremental EBITDA from Jagsonpal brands + margin recovery in hospital segment.

Numbers will speak in next 2 quarters. Hardest challenge: negotiating win-win with aggressive hospital procurement teams. Aequitas's 49-person lean team with deep hospital relationships is the moat and learning opportunity.

Pharmarack data: ₹46 Cr total (₹34 Cr injections + ₹13 Cr tablets). Growing ahead of molecule market. Top 3 brand for JPL; extremely value-accretive but will not fully explain overall portfolio growth.

Cannot disclose exact PCPM but targeting upward of ₹2,50,000 across business. Each vertical (dermatology, gynecology, orthopedics, GPCP) has different PCPM; no single number suffices.

ICU usage portfolio: antibiotics, volume enhancers, perioperative injectables, pain relievers. All branded; no government tenders. Top 10 products ~50% of sales; 50 hospitals of 1,000 drive majority. High headroom to grow.

Power brands: Indocap, Endoreg, Maintane, Eukroma, KTC. All have strong retail equity; hospital channel is fresh entry point.

Aequitas will remain subsidiary (not BTA). Different WC cycles for each. Aequitas cycle longer; we intend to improve but won't force alignment with JPL.

Aequitas alone: ₹100 Cr revenue in 2.5 years (by FY28-29), with ₹10 Cr+ EBITDA. Breakdown: existing organic acceleration + new Jagsonpal brands into hospital + innovative products.

Brand doing well internally; other brands (Metadec, Lycored, Equirex, Divatrone, Endoreg, Pru) also growing better than market. Growth momentum to accelerate in coming quarters.

Pan-India presence. Top 6: Max, Manipal, Vedanta, Cloudnine, Rainbow, Aster DM. Yes, these are primary growth drivers.

Not mentioned in prior calls. Pursuing first-to-launch in gynae/ortho/derma. Launched one first-wave product this quarter; expect one more in current quarter.

Indocap (largest, scope for exponential growth), Maintane (already strong), Endoreg (mainstay in gynecology), Pru and Eukroma (dermatology focus).

Inventory control as primary driver (68 days → 51 days). Collection cycles stringent (maintained ~20 days despite organic growth). Creditor management aligned. Digital transformation + hundreds of small initiatives, not one singular factor.

Hospital segment inherently thinner. Doctors choose brands; hospitals choose price first, brand second. Comparable to all large players in hospital channel. Margins will improve via product mix (higher-margin innovatives) and productivity.

Both. Primary: product mix improvement (shift to higher-margin innovatives). Secondary: productivity and operating leverage. Early-stage; clearer progress expected in coming quarters.

Prior guidance reiterated but Q1 at 9% implies acceleration needed; secondary sales data (18.9%) not reconciled to primary (9%), raising demand visibility questions.

Q1 OPM 21%, NPM 15.5% achieved; brand shift and lean initiatives delivering. Aequitas will dilute blended margins near-term but hospital segment margins expected to recover.

No specific capex number disclosed; management focused on M&A and shareholder returns. Aequitas integration and Jagsonpal scale-up to drive organic reinvestment.

Q1 revenue 9% vs implied 12-15% FY27 target. To achieve 12-15% FY27, subsequent quarters need 13-18% growth, creating pressure. If secondary sales gap reflects inventory build rather than demand, guidance at risk.

₹20.8 Cr acquisition targeting ₹10 Cr EBITDA by year 2 from ₹0.5 Cr base—20x increase. Hospital margins inherently thin (vs 65%+ core); cross-sell success uncertain; team is small (49) and integration complex.

Maintane (₹46 Cr Pharmarack value) and Indocap driving disproportionate growth. If either brand slows or faces patent/competitive pressure, portfolio growth stalls. Management acknowledged but downplayed via other brand progress.

Pharmarack secondary data (18.9%) vs reported primary revenue (9%) gap of 10 pp unexplained. If driven by channel inventory build rather than underlying demand, growth may decelerate once inventory normalizes.

Hospital segment gross margins ~15-18% (vs core 65%+) will dilute blended margins. Cross-sell and product mix improvement needed to offset; timeline unclear.